MEDIA
Publications
Poster: Phase Ia/Ib study of RS-0139 a novel tumor-targeted delivery of docetaxel, in patients with recurrent, locally advanced, or metastatic non-small cell lung cancer
European Society for Medical Oncology 2022 Congress
September 2022
RS Research is a biotechnology start-up discovering and developing smart nanomedicines for targeted chemotherapy. Our innovative drug delivery technology can increase the effect of chemotherapy while reducing side effects in multiple indications for a “Cure with A Smile”.